Rab22a is a novel prognostic marker for cell progression in breast cancer

Int J Mol Med 45: 1037-1046, 2020; DOI: 10.3892/ijmm.2020.4486

Following the publication of this article, the authors have realized that Table I contained an error: The number of patients who were alive in the Rab22a high expression group should have been written as 77 instead of 772.

Table I.

Clinicopathological characteristics of patient samples and expression of Rab22a in breast cancer.

Characteristics	Rab22a expression			P-value
	Low	Middle	High
Age, years
<50	20	58	45
≥50	10	67	58	0.079
Menopause stage
No	20	68	55
Yes	10	57	48	0.415
Age at menarche, years
<15	19	71	39
≥15	11	54	64	0.005
Clinical stage
I	17	49	32
II	7	57	34
III	6	19	37	0.001
T classification
T1	22	80	53
T2	8	40	40
T3	0	5	9
T4	0	0	1	0.148
N classification
N0	19	71	47
N1	5	35	22
N2	2	13	13
N3	4	6	21	0.013
Nipple invasion
No	30	124	97
Yes	0	1	6	0.042
Venous invasion
No	23	90	60
Yes	7	35	43	0.044
Nerve invasion
No	26	99	82
Yes	4	26	21	0.640
Basal invasion
No	30	124	101
Yes	0	1	2	0.595
Pectoralis minor muscle invasion
No	30	124	101
Yes	0	1	2	0.595
Pathological differentiation
G1	4	10	7
G2	23	85	73
G3	3	30	23	0.446
ER status
Negative	5	32	33
Positive	25	93	70	0.216
PR status
Negative	6	41	40
Positive	24	84	63	0.151
Expression of Her-2
Negative	22	91	63
Positive	8	34	40	0.140
Expression of Ki67
Low expression	24	88	64
High expression	6	37	39	0.139
Molecular classification
Luminal A	15	48	24
Luminal B (Her-2-)	7	21	25
Luminal B (Her-2+)	3	25	23
Her-2+	3	13	16
Basal like	2	18	15	0.131
Vital status (at follow-up)
Alive	28	112	77
Dead	2	13	26	0.003

T, tumor; M, metastasis; N, node; ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor-2.

A corrected version of the Table is shown on the next page (the corrected datum is highlighted in bold). The authors sincerely apologize for the error that was introduced during the preparation of this Table, and regret any inconvenience that this mistake has caused.